All In Biotech

Drug Trial Radar · NCT06714253

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

A Phase I/IIa, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Intraductal Administration of RXRG001 to Parotid Gland(s) in Adults With Radiation-Induced Xerostomia and Hyposalivation

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Mar 5, 2025

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
RiboX Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Dec 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human clinical study to evaluate the safety, tolerability and efficacy of RXRG001 administered in the ducts of the parotid glands in adult patients with radiation-induced xerostomia (dry mouth) and hyposalivation (reduced saliva production). In Part 1 of the study (open-label, single-arm), patients will receive unilateral administrations of RXRG001 in 3 single ascending dose cohorts and in 3 multiple ascending dose cohorts. Part 2 of the study has a randomized, double-blind, placebo-controlled design. Patients will receive bilateral administrations of RXRG001 in 3 multiple ascending dose cohorts.

Conditions

  • Radiation-Induced Xerostomia and Hyposalivation

Interventions

  • RXRG001Biological

    Circular ribonucleic acid encoding human aquaporin 1 encapsulated in a lipid nanoparticle

  • PlaceboBiological

    Placebo (saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: Part 1: up to 60 weeks, Part 2: up to 60 weeks
  2. Incidence of treatment-emergent serious adverse eventsTime frame: Part 1: up to 60 weeks, Part 2: up to 60 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford Medicine

    Palo Alto, California · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • John Hopkins University, Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • NYU Langone Medical Center

    New York, New York · Recruiting

  • Penn Medicine - Otorhinolaryngology - Head and Neck Surgery Perelman

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.